Research programme: bispecific antibodies - Janssen Biotech
Latest Information Update: 09 Mar 2023
At a glance
- Originator Janssen Biotech
- Class Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified